Immunogenomics uncovers genetic variants and B cell dysfunction in rheumatoid arthritis, suggesting new therapeutic interventions.
This article focused on abberant B cell activation and immunogenomics aspects of B cells in rheumatoid arthritis. Precise identification of abberant BCR signalling pathways, abberant genetic variats and extensive abnormalities in DNA can provide detailed insights to direct structural and therapeutic interventions against autoimmune and hypersensitive disorders.
No takes yet. Share an insight, caveat, or question.
HANEEF et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: